CTLT
Catalent, Inc.
- Latest sale
- $167k
- Nov 11 · No plan
- Form 4 sales
- 195
- On record
- Form 144 notices
- 29
- Proposed sales
- Next unlock
- None
- No lockup ahead
Lockups
No lockup on record.
Sales by reason
Timeline
- 1 Form 4 saleUnusualAug 2 2024
Sold 1,169 shares at $59.55 ($70k)
Gennadios Aristippos, Group Pres. Pharma & Consumer
No 10b5-1 planSold 1% of holdings ($6.8M position)113,724 shares left3.1x usual sizeFiling
- 2 Form 4 saleNo planAug 2 same day
Sold 3,859 shares at $59.67 ($230k)
Evoli Lisa, SVP, Chief HR Officer
No 10b5-1 planSold 8.9% of holdings ($2.6M position)39,366 shares leftFirst sale on recordFiling
- 3 Form 4 saleNo planAug 2 same day
Sold 608 shares at $59.58 ($36k)
Ferraro Joseph Anthony, SVP, General Counsel, CCO
No 10b5-1 planSold 2.4% of holdings ($1.5M position)24,287 shares leftFirst sale on recordFiling
- 4 Form 4 saleNo planAug 2 same day
Sold 666 shares at $59.55 ($40k)
Gunther Scott, SVP, Quality & Reg. Affairs
No 10b5-1 planSold 1.7% of holdings ($2.4M position)39,635 shares left2x usual sizeFiling
- 5 Form 4 saleNo planAug 2 same day
Sold 662 shares at $59.56 ($39k)
Hopson Ricky, Pres. BioProduct Delivery, CoS
No 10b5-1 planSold 2.2% of holdings ($1.8M position)29,974 shares left1x usual sizeFiling
- 6 Form 4 saleNo planSep 26 +55 days
Sold 1,994 shares at $59.97 ($120k)
McErlane David, Group President, Biologics
No 10b5-1 planSold 5.2% of holdings ($2.3M position)36,304 shares leftFirst sale on recordFiling
- 7 Form 4 saleNo planOct 18 +22 days
Sold 320 shares at $59.97 ($19k)
Ferraro Joseph Anthony, SVP, General Counsel, CCO
No 10b5-1 planSold 1.3% of holdings ($1.5M position)23,967 shares leftFiling
- 8 Form 4 saleNo planNov 11 +24 days
Sold 2,800 shares at $59.70 ($167k)
Ryan Michelle R, Director
No 10b5-1 planSold 20.5% of holdings ($814k position)10,835 shares leftFirst sale on recordFiling
Every transaction
Loading transactions…
Sales, notices and lockups (224)
Export watchlist as CSV| Source | ||||||||
|---|---|---|---|---|---|---|---|---|
| Nov 11, 2024 | Ryan Michelle R | Director | Form 4 sale | 2,800 | $167k | 20.5% | No plan | SEC |
| Oct 18, 2024 | Ferraro Joseph Anthony | SVP, General Counsel, CCO | Form 4 sale | 320 | $19k | 1.3% | No plan | SEC |
| Sep 26, 2024 | McErlane David | Group President, Biologics | Form 4 sale | 1,994 | $120k | 5.2% | No plan | SEC |
| Aug 2, 2024 | Hopson Ricky | Pres. BioProduct Delivery, CoS | Form 4 sale | 662 | $39k | 2.2% | No plan | SEC |
| Aug 2, 2024 | Gunther Scott | SVP, Quality & Reg. Affairs | Form 4 sale | 666 | $40k | 1.7% | No plan | SEC |
| Aug 2, 2024 | Ferraro Joseph Anthony | SVP, General Counsel, CCO | Form 4 sale | 608 | $36k | 2.4% | No plan | SEC |
| Aug 2, 2024 | Evoli Lisa | SVP, Chief HR Officer | Form 4 sale | 3,859 | $230k | 8.9% | No plan | SEC |
| Aug 2, 2024 | Gennadios Aristippos | Group Pres. Pharma & Consumer | Form 4 sale | 1,169 | $70k | 1.0% | Unusual | SEC |
| Jul 29, 2024 | Maselli Alessandro | President & CEO | Form 4 sale | 9,088 | $534k | 4.9% | Unusual | SEC |
| Jul 29, 2024 | Hopson Ricky | Pres. BioProduct Delivery, CoS | Form 4 sale | 206 | $12k | 0.7% | No plan | SEC |
| Jul 29, 2024 | Gunther Scott | SVP, Quality & Reg. Affairs | Form 4 sale | 283 | $17k | 0.7% | No plan | SEC |
| Jul 29, 2024 | Gennadios Aristippos | Group Pres. Pharma & Consumer | Form 4 sale | 349 | $20k | 0.3% | No plan | SEC |
| Jul 8, 2024 | Masanovich Matti | SVP, Chief Financial Officer | Form 4 sale | 2,993 | $170k | 8.1% | No plan | SEC |
| Jun 4, 2024 | Hopson Ricky | Pres. BioProduct Delivery, CoS | Form 4 sale | 1,401 | $76k | 6.4% | No plan | SEC |
| Mar 15, 2024 | Gunther Scott | SVP, Quality & Reg. Affairs | Form 4 sale | 387 | $22k | 1.3% | Routine | SEC |
| Aug 24, 2023 | Maselli Alessandro | President & CEO | Form 4 sale | 2,071 | $92k | 2.3% | No plan | SEC |
| Aug 24, 2023 | Gunther Scott | SVP, Quality & Reg. Affairs | Form 4 sale | 269 | $12k | 0.9% | No plan | SEC |
| Aug 24, 2023 | Grippo Michael J | SVP, Strategy & Corp. Dev. | Form 4 sale | 390 | $17k | 1.6% | No plan | SEC |
| Aug 24, 2023 | Gennadios Aristippos | Group Pres. Pharma & Consumer | Form 4 sale | 396 | $18k | 0.4% | No plan | SEC |
| Aug 24, 2023 | Fasman Steven L | EVP & Chief Admin Officer | Form 4 sale | 817 | $36k | 1.1% | No plan | SEC |
| Aug 24, 2023 | Carletti Lorenzo | SVP Global Ops Ph & Cons Hlth | Form 4 sale | 216 | $10k | 2.4% | No plan | SEC |
| Aug 24, 2023 | Arnold Jonathan | SVP, CCO & Div. Head BioP Del. | Form 4 sale | 87 | $4k | 0.2% | No plan | SEC |
| Aug 24, 2023 | Hopson Ricky | Pres. Clinical Dev Supply Div | Form 4 sale | 276 | $12k | 1.2% | No plan | SEC |
| Aug 24, 2023 | Hawkeswood Thomas W | Pres. Pharma Prod Delivery Div | Form 4 sale | 147 | $7k | 1.9% | No plan | SEC |
| Aug 24, 2023 | Lickfold Charles | SVP, CIO | Form 4 sale | 190 | $8k | 1.6% | No plan | SEC |
| Aug 24, 2023 | Hunt Patricia | Pres. Consumer Health Div | Form 4 sale | 106 | $5k | 0.9% | No plan | SEC |
| Aug 24, 2023 | Pravda Ricardo | Chief Transformation Officer | Form 4 sale | 379 | $17k | 1.2% | No plan | SEC |
| Aug 24, 2023 | Lickfold Charles | Officer | Form 144 notice | 190 | $8k | Notice | SEC | |
| Aug 24, 2023 | Hawkeswood Thomas W | Officer | Form 144 notice | 147 | $7k | Notice | SEC | |
| Aug 24, 2023 | Fasman Steven L | Officer | Form 144 notice | 817 | $36k | Notice | SEC | |
| Aug 24, 2023 | Hopson Ricky | Officer | Form 144 notice | 276 | $12k | Notice | SEC | |
| Aug 24, 2023 | Maselli Alessandro | Officer, Director | Form 144 notice | 2,071 | $92k | Notice | SEC | |
| Aug 24, 2023 | Pravda Ricardo | Officer | Form 144 notice | 379 | $17k | Notice | SEC | |
| Aug 24, 2023 | Grippo Michael J | Officer | Form 144 notice | 390 | $17k | Notice | SEC | |
| Aug 24, 2023 | Hunt Patricia | Officer | Form 144 notice | 106 | $5k | Notice | SEC | |
| Aug 24, 2023 | Arnold Jonathan | Officer | Form 144 notice | 87 | $4k | Notice | SEC | |
| Aug 24, 2023 | Gunther Scott | Officer | Form 144 notice | 269 | $12k | Notice | SEC | |
| Aug 24, 2023 | Carletti Lorenzo | Officer | Form 144 notice | 216 | $10k | Notice | SEC | |
| Aug 24, 2023 | Gennadios Aristippos | Officer | Form 144 notice | 396 | $18k | Notice | SEC | |
| Aug 1, 2023 | Pravda Ricardo | Chief Transformation Officer | Form 4 sale | 269 | $13k | 1.3% | No plan | SEC |
| Aug 1, 2023 | Maselli Alessandro | President & CEO | Form 4 sale | 1,485 | $70k | 1.7% | No plan | SEC |
| Aug 1, 2023 | Lickfold Charles | SVP, CIO | Form 4 sale | 135 | $6k | 2.4% | No plan | SEC |
| Aug 1, 2023 | Hunt Patricia | Pres. Consumer Health Div | Form 4 sale | 161 | $8k | 1.7% | No plan | SEC |
| Aug 1, 2023 | Hopson Ricky | Pres. Clinical Dev Supply Div | Form 4 sale | 195 | $9k | 1.2% | No plan | SEC |
| Aug 1, 2023 | Hawkeswood Thomas W | Pres. Pharma Prod Delivery Div | Form 4 sale | 258 | $12k | 4.8% | No plan | SEC |
| Aug 1, 2023 | Gunther Scott | SVP, Quality & Reg. Affairs | Form 4 sale | 190 | $9k | 0.8% | No plan | SEC |
| Aug 1, 2023 | Grippo Michael J | SVP, Strategy & Corp. Dev. | Form 4 sale | 276 | $13k | 1.6% | No plan | SEC |
| Aug 1, 2023 | Gennadios Aristippos | Group Pres. Pharma & Consumer | Form 4 sale | 281 | $13k | 0.3% | No plan | SEC |
| Aug 1, 2023 | Carletti Lorenzo | SVP Global Ops Ph & Cons Hlth | Form 4 sale | 383 | $18k | 7.7% | No plan | SEC |
| Aug 1, 2023 | Arnold Jonathan | SVP, CCO & Div. Head BioP Del. | Form 4 sale | 62 | $3k | 0.1% | No plan | SEC |
| Aug 1, 2023 | Fasman Steven L | EVP & Chief Admin Officer | Form 4 sale | 1,637 | $77k | 2.6% | No plan | SEC |
| Aug 1, 2023 | Maselli Alessandro | Officer, Director | Form 144 notice | 1,485 | $70k | Notice | SEC | |
| Aug 1, 2023 | Schmidt Kay A | Officer | Form 144 notice | 261 | $12k | Notice | SEC | |
| Aug 1, 2023 | Pravda Ricardo | Former Chief Human Resources Officer | Form 144 notice | 269 | $13k | Notice | SEC | |
| Aug 1, 2023 | Gunther Scott | Officer | Form 144 notice | 190 | $9k | Notice | SEC | |
| Aug 1, 2023 | Hunt Patricia | Officer | Form 144 notice | 161 | $8k | Notice | SEC | |
| Aug 1, 2023 | Hawkeswood Thomas W | Officer | Form 144 notice | 258 | $12k | Notice | SEC | |
| Aug 1, 2023 | Chiminski John R | Former Board of Director | Form 144 notice | 7,817 | $367k | Notice | SEC | |
| Aug 1, 2023 | Hopson Ricky | Officer | Form 144 notice | 195 | $9k | Notice | SEC | |
| Aug 1, 2023 | Gennadios Aristippos | Officer | Form 144 notice | 281 | $13k | Notice | SEC | |
| Aug 1, 2023 | Fasman Steven L | Officer | Form 144 notice | 1,637 | $77k | Notice | SEC | |
| Aug 1, 2023 | Lickfold Charles | Officer | Form 144 notice | 135 | $6k | Notice | SEC | |
| Aug 1, 2023 | Boerman Manja | Officer | Form 144 notice | 574 | $27k | Notice | SEC | |
| Aug 1, 2023 | Grippo Michael J | Officer | Form 144 notice | 276 | $13k | Notice | SEC | |
| Aug 1, 2023 | Arnold Jonathan | Officer | Form 144 notice | 62 | $3k | Notice | SEC | |
| Aug 1, 2023 | Carletti Lorenzo | Officer | Form 144 notice | 383 | $18k | Notice | SEC | |
| May 1, 2023 | Boerman Manja | Pres. BioModalities Division | Form 4 sale | 1,446 | $72k | 9.1% | No plan | SEC |
| May 1, 2023 | Gargiulo Mario | SVP, Ops, Biologics Europe | Form 4 sale | 678 | $34k | 10.7% | No plan | SEC |
| May 1, 2023 | Gargiulo Mario | Officer | Form 144 notice | 678 | $34k | Notice | SEC | |
| May 1, 2023 | Boerman Manja | Officer | Form 144 notice | 1,446 | $72k | Notice | SEC | |
| Jan 23, 2023 | Hopson Ricky | Pres. Clinical Dev Supply Div | Form 4 sale | 643 | $32k | 3.8% | Plan not stated | SEC |
| Dec 5, 2022 | Boerman Manja | Pres. BioModalities Division | Form 4 sale | 780 | $40k | 4.7% | Plan not stated | SEC |
| Oct 31, 2022 | Grippo Michael J | SVP, Strategy & Corp. Dev. | Form 4 sale | 2,451 | $161k | 12.1% | Plan not stated | SEC |
| Oct 10, 2022 | Hawkeswood Thomas W | Pres. Pharma Prod Delivery Div | Form 4 sale | 930 | $72k | 14.8% | Plan not stated | SEC |
| Aug 31, 2022 | Hopson Ricky | Pres. Clinical Dev Supply Div | Form 4 sale | 2,216 | $199k | 11.5% | Plan not stated | SEC |
| Aug 26, 2022 | Riley Michael A. | Pres. Bio Product Delivery Div | Form 4 sale | 2,491 | $259k | 27.4% | Unusual | SEC |
| Aug 26, 2022 | Gunther Scott | SVP, Quality & Reg. Affairs | Form 4 sale | 1,639 | $171k | 6.4% | Plan not stated | SEC |
| Aug 25, 2022 | Schmidt Kay A | SVP, Enterprise Functions | Form 4 sale | 1,321 | $136k | 7.1% | Plan not stated | SEC |
| Aug 25, 2022 | Riley Michael A. | Pres. Bio Product Delivery Div | Form 4 sale | 1,482 | $153k | 14.0% | Plan not stated | SEC |
| Aug 25, 2022 | Pravda Ricardo | SVP & Chief HR Officer | Form 4 sale | 1,747 | $180k | 8.0% | Unusual | SEC |
| Aug 25, 2022 | Maselli Alessandro | President & CEO | Form 4 sale | 4,646 | $479k | 10.1% | Unusual | SEC |
| Aug 25, 2022 | Hunt Patricia | Pres. Consumer Health Div | Form 4 sale | 339 | $35k | 3.5% | Plan not stated | SEC |
| Aug 25, 2022 | Hopson Ricky | Pres. Clinical Dev Supply Div | Form 4 sale | 1,517 | $156k | 7.3% | Plan not stated | SEC |
| Aug 25, 2022 | Hawkeswood Thomas W | Pres. Pharma Prod Delivery Div | Form 4 sale | 671 | $69k | 9.6% | Plan not stated | SEC |
| Aug 25, 2022 | Gunther Scott | SVP, Quality & Reg. Affairs | Form 4 sale | 1,840 | $190k | 6.7% | Plan not stated | SEC |
| Aug 25, 2022 | Grippo Michael J | SVP, Strategy & Corp. Dev. | Form 4 sale | 1,670 | $172k | 7.6% | Plan not stated | SEC |
| Aug 25, 2022 | Gennadios Aristippos | Group Pres. Pharma & Consumer | Form 4 sale | 1,645 | $170k | 1.9% | Unusual | SEC |
| Aug 25, 2022 | Gargiulo Mario | SVP Global Ops Biologics | Form 4 sale | 1,586 | $163k | 20.0% | Plan not stated | SEC |
| Aug 25, 2022 | Fasman Steven L | EVP & Chief Admin Officer | Form 4 sale | 4,811 | $496k | 7.2% | Plan not stated | SEC |
| Aug 25, 2022 | Chiminski John R | Executive Chair | Form 4 sale | 38,934 | $4M | 14.5% | Plan not stated | SEC |
| Aug 25, 2022 | Castellano Thomas P | SVP, Chief Financial Officer | Form 4 sale | 1,414 | $146k | 6.6% | Plan not stated | SEC |
| Aug 25, 2022 | Carletti Lorenzo | SVP Global Ops Ph & Cons Hlth | Form 4 sale | 1,033 | $106k | 17.2% | Plan not stated | SEC |
| Aug 25, 2022 | Boerman Manja | Pres. BioModalities Division | Form 4 sale | 3,296 | $340k | 16.5% | Plan not stated | SEC |
| Aug 25, 2022 | Arnold Jonathan | SVP & Chief Commercial Ofcr | Form 4 sale | 384 | $40k | 0.7% | Plan not stated | SEC |
| Jul 27, 2022 | Hopson Ricky | Pres, Clinical Dev & Supply | Form 4 sale | 903 | $97k | 5.0% | Plan not stated | SEC |
| Jul 27, 2022 | Gunther Scott | SVP, Quality & Reg. Affairs | Form 4 sale | 844 | $91k | 3.6% | Plan not stated | SEC |
| Jul 27, 2022 | Grippo Michael J | SVP, Strategy & Corp. Dev. | Form 4 sale | 797 | $85k | 4.5% | Plan not stated | SEC |
| Jul 26, 2022 | Schmidt Kay A | SVP, Enterprise Functions | Form 4 sale | 323 | $35k | 2.3% | Plan not stated | SEC |
| Jul 26, 2022 | Pravda Ricardo | SVP & Chief HR Officer | Form 4 sale | 427 | $46k | 2.7% | Plan not stated | SEC |
| Jul 26, 2022 | Maselli Alessandro | President & CEO | Form 4 sale | 816 | $87k | 3.2% | Plan not stated | SEC |
| Jul 26, 2022 | Gennadios Aristippos | Group Pres. Pharma & Consumer | Form 4 sale | 403 | $43k | 0.5% | Plan not stated | SEC |
| Jul 26, 2022 | Gargiulo Mario | SVP Global Ops Biologics | Form 4 sale | 969 | $104k | 20.9% | Plan not stated | SEC |
| Jul 26, 2022 | Fasman Steven L | EVP & Chief Admin Officer | Form 4 sale | 2,546 | $272k | 4.5% | Plan not stated | SEC |
| Jul 26, 2022 | Chiminski John R | Executive Chair | Form 4 sale | 9,691 | $1M | 6.8% | Plan not stated | SEC |
| Jul 26, 2022 | Castellano Thomas P | SVP, Chief Financial Officer | Form 4 sale | 347 | $37k | 2.3% | Plan not stated | SEC |
| Jul 26, 2022 | Carletti Lorenzo | SVP Global Ops Ph & Cons Hlth | Form 4 sale | 631 | $67k | 17.6% | Plan not stated | SEC |
| Jul 26, 2022 | Arnold Jonathan | SVP & Chief Commercial Ofcr | Form 4 sale | 94 | $10k | 0.2% | Plan not stated | SEC |
| Jun 10, 2022 | Gargiulo Mario | SVP Global Ops Large Molecule | Form 4 sale | 118 | $13k | 2.5% | Plan not stated | SEC |
| Jun 10, 2022 | Fasman Steven L | SVP & General Counsel | Form 4 sale | 5,000 | $535k | 8.2% | Plan not stated | SEC |
| Feb 6, 2022 | Zippelius Peter | Director | Form 4 sale | 487,092 | $50M | 10.1% | Plan not stated | SEC |
| Jan 31, 2022 | Hopson Ricky | VP, Chief Accounting Officer | Form 4 sale | 2,325 | $240k | 12.0% | Plan not stated | SEC |
| Jan 21, 2022 | Whitlow Ricci S | President, CSS | Form 4 sale | 184 | $19k | 5.9% | Plan not stated | SEC |
| Jan 10, 2022 | Flynn Karen | Chief Commercial Officer | Form 4 sale | 2,472 | $288k | 6.9% | Plan not stated | SEC |
| Nov 30, 2021 | Name not stated | Director | Form 4 sale | 3M | $388M | 38.3% | Unusual | SEC |
| Nov 23, 2021 | Lucier Gregory T | Director | Form 4 sale | 5,068 | $645k | 100.0% | Unusual | SEC |
| Nov 1, 2021 | Arnold Jonathan | Pres. Oral & Specialty Deliv. | Form 4 sale | 10,672 | $1.5M | 20.3% | Unusual | SEC |
| Oct 20, 2021 | Castellano Thomas P | SVP, Chief Financial Officer | Form 4 sale | 2,307 | $309k | 13.0% | Plan not stated | SEC |
| Oct 14, 2021 | Arnold Jonathan | Pres. Oral & Specialty Deliv. | Form 4 sale | 1,661 | $215k | 3.6% | Unusual | SEC |
| Oct 4, 2021 | Schmidt Kay A | SVP, Technical Operations | Form 4 sale | 2,191 | $288k | 13.7% | Plan not stated | SEC |
| Oct 4, 2021 | Fasman Steven L | SVP & General Counsel | Form 4 sale | 34,714 | $4.5M | 37.8% | Unusual | SEC |
| Oct 1, 2021 | Pravda Ricardo | SVP & Chief HR Officer | Form 4 sale | 4,906 | $651k | 29.5% | Unusual | SEC |
| Oct 1, 2021 | Grippo Michael J | SVP, Strategy & Corp. Dev. | Form 4 sale | 2,055 | $271k | 14.1% | Plan not stated | SEC |
| Oct 1, 2021 | Chiminski John R | Chair & CEO | Form 4 sale | 152,637 | $20M | 51.8% | Unusual | SEC |
| Aug 27, 2021 | Castellano Thomas P | SVP, Chief Financial Officer | Form 4 sale | 2,093 | $274k | 10.6% | Plan not stated | SEC |
| Aug 27, 2021 | Schmidt Kay A | SVP, Technical Operations | Form 4 sale | 825 | $108k | 4.9% | Plan not stated | SEC |
| Aug 27, 2021 | Hopson Ricky | VP, Chief Accounting Officer | Form 4 sale | 1,471 | $193k | 7.0% | Plan not stated | SEC |
| Aug 27, 2021 | Pravda Ricardo | SVP & Chief HR Officer | Form 4 sale | 692 | $91k | 5.1% | Plan not stated | SEC |
| Aug 27, 2021 | Maselli Alessandro | President & COO | Form 4 sale | 3,743 | $491k | 12.6% | Unusual | SEC |
| Aug 27, 2021 | Gunther Scott | SVP, Quality & Reg. Affairs | Form 4 sale | 4,173 | $546k | 18.8% | Unusual | SEC |
| Aug 27, 2021 | Grippo Michael J | SVP, Strategy & Corp. Dev. | Form 4 sale | 1,698 | $223k | 10.4% | Plan not stated | SEC |
| Aug 27, 2021 | Gennadios Aristippos | President Softgel & Oral Tech | Form 4 sale | 2,262 | $297k | 3.8% | Plan not stated | SEC |
| Aug 27, 2021 | Fasman Steven L | SVP & General Counsel | Form 4 sale | 6,111 | $801k | 7.6% | Plan not stated | SEC |
| Aug 27, 2021 | Chiminski John R | Chair & CEO | Form 4 sale | 44,488 | $5.8M | 16.2% | Plan not stated | SEC |
| Aug 27, 2021 | Arnold Jonathan | Pres. Oral & Specialty Deliv. | Form 4 sale | 452 | $59k | 1.0% | Unusual | SEC |
| Jul 26, 2021 | Castellano Thomas P | SVP, Chief Financial Officer | Form 4 sale | 555 | $63k | 3.7% | Plan not stated | SEC |
| Jul 26, 2021 | Schmidt Kay A | SVP, Technical Operations | Form 4 sale | 547 | $62k | 3.9% | Plan not stated | SEC |
| Jul 26, 2021 | Hopson Ricky | VP, Chief Accounting Officer | Form 4 sale | 360 | $41k | 2.2% | Plan not stated | SEC |
| Jul 26, 2021 | Pravda Ricardo | SVP & Chief HR Officer | Form 4 sale | 458 | $52k | 4.1% | Plan not stated | SEC |
| Jul 26, 2021 | Maselli Alessandro | President & COO | Form 4 sale | 993 | $112k | 5.1% | Plan not stated | SEC |
| Jul 26, 2021 | Gunther Scott | SVP, Quality & Reg. Affairs | Form 4 sale | 1,079 | $122k | 6.5% | Plan not stated | SEC |
| Jul 26, 2021 | Grippo Michael J | SVP, Strategy & Corp. Dev. | Form 4 sale | 451 | $51k | 2.6% | Plan not stated | SEC |
| Jul 26, 2021 | Gennadios Aristippos | President Softgel & Oral Tech | Form 4 sale | 465 | $53k | 0.9% | Plan not stated | SEC |
| Jul 26, 2021 | Fasman Steven L | SVP & General Counsel | Form 4 sale | 1,549 | $175k | 2.2% | Plan not stated | SEC |
| Jul 26, 2021 | Chiminski John R | Chair & CEO | Form 4 sale | 11,137 | $1.3M | 6.8% | Plan not stated | SEC |
| Jul 26, 2021 | Arnold Jonathan | Pres. Oral & Specialty Deliv. | Form 4 sale | 120 | $14k | 0.3% | Plan not stated | SEC |
| Jul 15, 2021 | Fasman Steven L | SVP & General Counsel | Form 4 sale | 4,500 | $494k | 6.1% | Plan not stated | SEC |
| Jun 23, 2021 | Pravda Ricardo | SVP & Chief HR Officer | Form 4 sale | 2,800 | $310k | 20.2% | Plan not stated | SEC |
| Mar 22, 2021 | Schmidt Kay A | SVP, Technical Operations | Form 4 sale | 1,400 | $148k | 9.2% | Plan not stated | SEC |
| Mar 19, 2021 | Chiminski John R | Chair & CEO | Form 4 sale | 225,244 | $23.8M | 57.9% | Unusual | SEC |
| Mar 18, 2021 | Fasman Steven L | SVP & General Counsel | Form 4 sale | 21,647 | $2.3M | 22.8% | Unusual | SEC |
| Feb 16, 2021 | Joseph Wetteny | SVP & Chief Financial Officer | Form 4 sale | 5,000 | $623k | 9.1% | Plan not stated | SEC |
| Feb 8, 2021 | Joseph Wetteny | SVP & Chief Financial Officer | Form 4 sale | 4,604 | $524k | 8.5% | Plan not stated | SEC |
| Jan 21, 2021 | Whitlow Ricci S | President, CSS | Form 4 sale | 692 | $82k | 21.2% | Plan not stated | SEC |
| Jan 11, 2021 | Flynn Karen | Pres. Biologics & CCO | Form 4 sale | 2,478 | $278k | 6.7% | Plan not stated | SEC |
| Jan 6, 2021 | Gunther Scott | SVP, Quality & Reg. Affairs | Form 4 sale | 61 | $6k | 0.4% | Plan not stated | SEC |
| Jan 4, 2021 | Whitlow Ricci S | President, CSS | Form 4 sale | 83 | $9k | 2.5% | Plan not stated | SEC |
| Jan 4, 2021 | Schmidt Kay A | SVP, Technical Operations | Form 4 sale | 73 | $8k | 0.5% | Plan not stated | SEC |
| Jan 4, 2021 | Pravda Ricardo | SVP & Chief HR Officer | Form 4 sale | 78 | $8k | 0.6% | Plan not stated | SEC |
| Jan 4, 2021 | Maselli Alessandro | President & COO | Form 4 sale | 148 | $15k | 0.7% | Plan not stated | SEC |
| Jan 4, 2021 | Joseph Wetteny | SVP & Chief Financial Officer | Form 4 sale | 172 | $18k | 0.3% | Plan not stated | SEC |
| Jan 4, 2021 | Gunther Scott | SVP, Quality & Reg. Affairs | Form 4 sale | 120 | $13k | 0.7% | Plan not stated | SEC |
| Jan 4, 2021 | Grippo Michael J | SVP, Strategy & Corp. Dev. | Form 4 sale | 126 | $13k | 0.7% | Plan not stated | SEC |
| Jan 4, 2021 | Gennadios Aristippos | President Softgel & Oral Tech | Form 4 sale | 110 | $11k | 0.2% | Plan not stated | SEC |
| Jan 4, 2021 | Flynn Karen | Pres. Biologics & CCO | Form 4 sale | 99 | $10k | 0.3% | Plan not stated | SEC |
| Jan 4, 2021 | Fasman Steven L | SVP & General Counsel | Form 4 sale | 189 | $20k | 0.3% | Plan not stated | SEC |
| Jan 4, 2021 | Arnold Jonathan | Pres. Oral & Specialty Deliv. | Form 4 sale | 16 | $2k | 0.0% | Plan not stated | SEC |
| Dec 21, 2020 | Gennadios Aristippos | President Softgel & Oral Tech | Form 4 sale | 13,662 | $1.4M | 21.0% | Plan not stated | SEC |
| Nov 23, 2020 | Zippelius Peter | Director | Form 4 sale | 5.4M | $535M | 100.0% | Unusual | SEC |
| Nov 11, 2020 | Fasman Steven L | SVP & General Counsel | Form 4 sale | 2,425 | $245k | 3.2% | Plan not stated | SEC |
| Oct 14, 2020 | Schmidt Kay A | SVP, Technical Operations | Form 4 sale | 2,985 | $278k | 15.9% | Plan not stated | SEC |
| Oct 14, 2020 | Fasman Steven L | SVP & General Counsel | Form 4 sale | 5,510 | $513k | 6.8% | Plan not stated | SEC |
| Oct 12, 2020 | Grippo Michael J | SVP, Strategy & Corp. Dev. | Form 4 sale | 1,680 | $160k | 8.9% | Plan not stated | SEC |
| Oct 7, 2020 | Arnold Jonathan | Pres. Oral & Specialty Deliv. | Form 4 sale | 15,928 | $1.5M | 29.2% | Unusual | SEC |
| Oct 2, 2020 | Gunther Scott | SVP, Quality & Reg. Affairs | Form 4 sale | 4,359 | $373k | 20.7% | Plan not stated | SEC |
| Oct 2, 2020 | Chiminski John R | Chair & CEO | Form 4 sale | 182,231 | $15.7M | 51.2% | Unusual | SEC |
| Sep 2, 2020 | Grippo Michael J | SVP, Strategy & Corp. Dev. | Form 4 sale | 2,250 | $201k | 10.6% | Plan not stated | SEC |
| Jul 30, 2020 | Lucier Gregory T | Director | Form 4 sale | 24,000 | $2.2M | 58.6% | Unusual | SEC |
| Jun 29, 2020 | Gunther Scott | SVP, Quality & Reg. Affairs | Form 4 sale | 2,824 | $203k | 17.4% | Plan not stated | SEC |
| Jun 25, 2020 | Gennadios Aristippos | President Softgel & Oral Tech | Form 4 sale | 8,325 | $608k | 15.8% | Plan not stated | SEC |
| Jan 13, 2020 | Grippo Michael J | SVP, Strategy & Corp. Dev. | Form 4 sale | 5,932 | $332k | 33.7% | Unusual | SEC |
| Dec 16, 2019 | Maselli Alessandro | President & COO | Form 4 sale | 7,268 | $387k | 36.2% | Unusual | SEC |
| Nov 26, 2019 | Pravda Ricardo | SVP & Chief HR Officer | Form 4 sale | 2,612 | $138k | 19.4% | Plan not stated | SEC |
| Nov 25, 2019 | Gennadios Aristippos | President Softgel & Oral Tech | Form 4 sale | 45,256 | $2.4M | 50.6% | Unusual | SEC |
| Nov 22, 2019 | Grippo Michael J | SVP, Strategy & Corp. Dev. | Form 4 sale | 376 | $20k | 3.4% | Plan not stated | SEC |
| Oct 7, 2019 | Chiminski John R | Chair & CEO | Form 4 sale | 97,043 | $4.7M | 30.2% | Unusual | SEC |
| Jul 12, 2019 | Littlejohns Barry | President, Biologics & SDD | Form 4 sale | 15,940 | $853k | 29.7% | Unusual | SEC |
| Jul 11, 2019 | Fasman Steven L | SVP & General Counsel | Form 4 sale | 4,053 | $219k | 7.7% | Plan not stated | SEC |
| Mar 21, 2019 | Gennadios Aristippos | President, Softgel Tech. | Form 4 sale | 3,392 | $143k | 8.9% | Plan not stated | SEC |
| Mar 7, 2019 | Miyamoto Lance | SVP, Human Resources | Form 4 sale | 43,619 | $1.9M | 48.2% | Unusual | SEC |
| Feb 15, 2019 | Downie William | SVP, Global Sales & Marketing | Form 4 sale | 7,315 | $307k | 17.3% | Plan not stated | SEC |
| Oct 16, 2018 | Miyamoto Lance | SVP, Human Resources | Form 4 sale | 6,525 | $277k | 12.2% | Plan not stated | SEC |
| Oct 15, 2018 | Littlejohns Barry | President, Biologics & SDD | Form 4 sale | 47,265 | $2M | 55.6% | Unusual | SEC |
| Oct 1, 2018 | Chiminski John R | Chair, President & CEO | Form 4 sale | 130,545 | $5.9M | 36.2% | Unusual | SEC |
| Jun 20, 2018 | Fasman Steven L | SVP & General Counsel | Form 4 sale | 2,252 | $94k | 4.9% | Plan not stated | SEC |
| Mar 8, 2018 | Downie William | SVP, Global Sales & Marketing | Form 4 sale | 9,082 | $380k | 20.4% | Plan not stated | SEC |
| Dec 12, 2017 | Chiminski John R | Chair, President & CEO | Form 4 sale | 181,458 | $7.2M | 44.1% | Unusual | SEC |
| Aug 29, 2017 | Miyamoto Lance | SVP - Human Resources | Form 4 sale | 8,512 | $325k | 17.2% | Plan not stated | SEC |
| Aug 29, 2017 | Dolan Christine | SVP - Product Development | Form 4 sale | 1,594 | $62k | 7.6% | Plan not stated | SEC |
| Aug 1, 2017 | Dolan Christine | SVP - Product Development | Form 4 sale | 745 | $26k | 5.0% | Plan not stated | SEC |
| Jun 9, 2017 | Walsh Matthew M | Officer | Form 4 sale | 27,748 | 22.8% | Plan not stated | SEC | |
| Apr 25, 2017 | Johnson Sharon | Officer | Form 4 sale | 9,160 | $266k | 22.9% | Plan not stated | SEC |
| Mar 20, 2017 | Downie William | Officer | Form 4 sale | 8,262 | $236k | 18.4% | Plan not stated | SEC |
| Mar 20, 2017 | Chiminski John R | Officer, Director | Form 4 sale | 73,819 | $2.1M | 28.4% | Unusual | SEC |
| Sep 9, 2016 | Blackstone Group L.P. | 10% owner | Form 4 sale | 17.1M | $403M | 100.0% | Unusual | SEC |
| Jun 9, 2016 | Blackstone Group Management L.L.C. | 10% owner | Form 4 sale | 8.8M | $215M | 33.9% | Unusual | SEC |
| May 27, 2016 | Walsh Matthew M | Officer | Form 4 sale | 21,197 | $612k | 19.4% | Plan not stated | SEC |
| Aug 19, 2015 | Chiminski John R | Officer, Director | Form 4 sale | 38,505 | $1.3M | 10.2% | Plan not stated | SEC |
| Aug 3, 2015 | Chiminski John R | Officer, Director | Form 4 sale | 35,277 | $1.2M | 9.4% | Plan not stated | SEC |
| Jul 27, 2015 | Walsh Matthew M | Officer | Form 4 sale | 27,172 | $847k | 24.4% | Plan not stated | SEC |
| Jul 20, 2015 | Chiminski John R | Officer, Director | Form 4 sale | 33,081 | $973k | 8.9% | Plan not stated | SEC |
| Jul 6, 2015 | Chiminski John R | Officer, Director | Form 4 sale | 33,828 | $993k | 9.0% | Plan not stated | SEC |
| Jun 11, 2015 | Blackstone Group L.P. | 10% owner | Form 4 sale | 1.8M | $51.9M | 6.7% | Plan not stated | SEC |
| Jun 8, 2015 | Blackstone Group Management L.L.C. | 10% owner | Form 4 sale | 12.3M | $346M | 30.7% | Unusual | SEC |
| Apr 6, 2015 | Walsh Matthew M | Officer | Form 4 sale | 34,439 | $1M | 29.0% | Unusual | SEC |
| Apr 1, 2015 | Houlton Scott | Officer | Form 4 sale | 16,253 | $498k | 32.3% | Unusual | SEC |
| Apr 1, 2015 | Gennadios Aristippos | Officer | Form 4 sale | 24,868 | $761k | 74.2% | Unusual | SEC |
| Mar 27, 2015 | Leonard Stephen | Officer | Form 4 sale | 31,005 | $934k | 41.0% | Unusual | SEC |
| Mar 9, 2015 | Blackstone Holdings III GP Management L.L.C. | 10% owner | Form 4 sale | 24M | 37.2% | Unusual | SEC | |
| Feb 17, 2015 | Johnson Sharon | Officer | Form 4 sale | 40,783 | $1.1M | 72.6% | Unusual | SEC |
| Feb 17, 2015 | Kurt Nielsen | Officer | Form 4 sale | 20,000 | $548k | 45.8% | Unusual | SEC |
| Feb 17, 2015 | Houlton Scott | Officer | Form 4 sale | 14,538 | $400k | 44.3% | Unusual | SEC |
| Feb 17, 2015 | Downie William | Officer | Form 4 sale | 46,080 | $1.3M | 67.4% | Unusual | SEC |
| Feb 13, 2015 | Leonard Stephen | Officer | Form 4 sale | 1,000 | $28k | 4.1% | Plan not stated | SEC |
| Feb 13, 2015 | Walsh Matthew M | Officer | Form 4 sale | 3,200 | $90k | 3.2% | Plan not stated | SEC |